StockData
Maravai LifeSciences Holdings, Inc. logo

Maravai LifeSciences Holdings, Inc. (MRVI) stock

MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)

Close on Nov 17, 2026Market cap $1.89BP/E –Yield –

Maravai LifeSciences r&d expenses

Research and development expenses are spending on new products and technology.

Maravai LifeSciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.22M, down 20.0% year over year. For fiscal 2025 it was $17.40M, down 9.5% from the year before. The highest annual figure on record is $19.22M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.40M-9.5%
FY2024Dec 31, 2024$19.22M+11.2%
FY2023Dec 31, 2023$17.28M-5.9%
FY2022Dec 31, 2022$18.37M+20.7%
FY2021Dec 31, 2021$15.22M+63.6%
FY2020Dec 31, 2020$9.30M+156.5%
FY2019Dec 31, 2019$3.63M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.70M-24.2%
Q1 FY2026Mar 31, 2026$3.89M-20.4%
Q4 FY2025Dec 31, 2025$3.79M-16.9%
Q3 FY2025Sep 30, 2025$3.84M-18.3%
Q2 FY2025Jun 30, 2025$4.88M-0.9%
Q1 FY2025Mar 31, 2025$4.89M-2.9%
Q4 FY2024Dec 31, 2024$4.56M-0.7%
Q3 FY2024Sep 30, 2024$4.70M+8.2%
Q2 FY2024Jun 30, 2024$4.92M+17.4%
Q1 FY2024Mar 31, 2024$5.03M+21.4%
Q4 FY2023Dec 31, 2023$4.59M-8.3%
Q3 FY2023Sep 30, 2023$4.35M-19.3%
Q2 FY2023Jun 30, 2023$4.19M-1.9%
Q1 FY2023Mar 31, 2023$4.15M+12.2%
Q4 FY2022Dec 31, 2022$5.01M-45.4%
Q3 FY2022Sep 30, 2022$5.39M+176.9%
Q2 FY2022Jun 30, 2022$4.27M+121.6%
Q1 FY2022Mar 31, 2022$3.70M+71.1%
Q4 FY2021Dec 31, 2021$9.18M+339.0%
Q3 FY2021Sep 30, 2021$1.95M+4.2%
Q2 FY2021Jun 30, 2021$1.93M+20.6%
Q1 FY2021Mar 31, 2021$2.16M-42.3%
Q4 FY2020Dec 31, 2020$2.09M–
Q3 FY2020Sep 30, 2020$1.87M–
Q2 FY2020Jun 30, 2020$1.60M–
Q1 FY2020Mar 31, 2020$3.74M–

More Maravai LifeSciences figures

See a number that looks wrong?